
Loading, please wait...

Loading, please wait...

Recent clinical findings highlight the potential of vaginal PRP injection as a therapeutic option for enhancing sexual health in women. Furthermore, a pilot randomized controlled trial (RCT) recently published in Obstetrics & Gynecology evaluated 52 premenopausal women. Specifically, researchers compared a one-time anterior vaginal wall injection of platelet-rich plasma (PRP) to a saline placebo.
Consequently, the study found that women treated with PRP experienced a significantly greater increase in their total Female Sexual Function Index (FSFI) scores. Moreover, at the six-week mark, the PRP group showed a median score change of 2.2 compared to only 0.3 in the control group. This improvement remained visible at the six-month follow-up. However, while subscale scores for desire, arousal, and lubrication improved, these specific changes did not reach statistical significance against the control. Additionally, nearly 70% of the PRP group reported overall improvement on the Patient Global Impression of Improvement (PGI-I) scale. Therefore, this suggests that the procedure is not only effective but also yields high patient satisfaction. Finally, clinicians reported no serious adverse events, confirming a favorable safety profile.
Platelet-rich plasma contains concentrated growth factors that stimulate tissue regeneration, improve blood flow, and enhance nerve sensitivity in the vaginal wall.
Yes, the latest clinical data indicates that the procedure is well-tolerated. In the randomized trial, participants reported no serious adverse events over a six-month period.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Clarke B et al. Vaginal Injection of Platelet-Rich Plasma for Sexual Function: A Randomized Controlled Trial. Obstet Gynecol. 2026 Mar 19. doi: 10.1097/AOG.0000000000006256. PMID: 41855531.
2. De Ponte A et al. Platelet-rich plasma in the management of vulvovaginal disorders: a systematic review. J Sex Med. 2026 Jan 5;23(1):qdaf307. doi: 10.1093/jsxmed/qdaf307. PMID: 41168677.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A recent RCT demonstrates that vaginal PRP injections significantly improve sexual function scores and patient satisfaction in premenopausal women....
7 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A 25-year multi-institutional cohort reveals high recurrence rates in pediatric giant cell tumor of bone, particularly in patients with open physes and bone marrow edema on preoperative MRI. Early surveillance and careful balance between growth plate preservation and tumor clearance are essential.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today